<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03077529</url>
  </required_header>
  <id_info>
    <org_study_id>163046</org_study_id>
    <nct_id>NCT03077529</nct_id>
  </id_info>
  <brief_title>GOS and Microbial Fermentation in Aging</brief_title>
  <official_title>Impact of Galacto-oligosaccharides on Microbial Fermentation Capacity and Markers of Frailty in Healthy Adults and Elderly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wageningen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The population is aging worldwide, concomitant frailty is increased in older age groups.&#xD;
      Frailty has a strong impact on outcomes of multi-morbidity and daily living, thereby&#xD;
      negatively influencing quality of life and health care costs. Prevention or delay of onset of&#xD;
      frailty associated with aging is needed. Dietary intake of galacto-oligosaccharides (GOS) may&#xD;
      have beneficial effects on microbiota composition and health outcome parameters. As&#xD;
      microbiota composition and function may be altered in elderly compared to younger adults, it&#xD;
      will investigated whether the effects of GOS on selected parameters of microbiota and gut&#xD;
      health differ between elderly versus younger adults. The primary objective of this study is&#xD;
      to compare the effects of four weeks GOS supplementation on intestinal microbiota composition&#xD;
      and activity in elderly versus younger adults. Further, this study has four secondary&#xD;
      objectives. The study conforms to a randomized double-blind placebo-controlled cross-over&#xD;
      design per age-group. Study populations are human volunteers (male and female), healthy young&#xD;
      adults of 25-50 years and prefail older adults of 70-85 years old, BMI 20-30 kg/m2. One&#xD;
      intervention period subjects will receive 7.2 grams of Vivinal® GOS Powder three times daily&#xD;
      for four weeks. The other intervention period subjects will receive isocaloric placebo&#xD;
      supplements (5.7 grams maltodextrin) three times daily for four weeks. At the start and end&#xD;
      of each intervention period, several measurements will take place. There will be a washout&#xD;
      period of four to five weeks between intervention periods. The main study parameter is the&#xD;
      change in microbial composition and activity induced by GOS intervention, in younger adults&#xD;
      and elderly.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 20, 2017</start_date>
  <completion_date type="Actual">September 6, 2018</completion_date>
  <primary_completion_date type="Actual">September 6, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Microbial composition</measure>
    <time_frame>Change from baseline to four weeks supplementation, of each intervention period</time_frame>
    <description>Microbiota composition and functional capacity as measured by HiSeq sequencing of fecal 16S rRNA genes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Microbial activity</measure>
    <time_frame>Change from baseline to four weeks supplementation, of each intervention period</time_frame>
    <description>Microbial activity as measured by metabolites, such as organic acids analysis in feces and plasma.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Healthy Young Adults</condition>
  <condition>Prefrail Elderly</condition>
  <arm_group>
    <arm_group_label>Galacto-oligosaccharide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During this period subjects will receive 5.65 grams of Vivinal GOS supplements three times daily for four weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maltodextrin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>During this period subjects will receive 7.24 grams of maltodextrin supplements three times daily for four weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Galacto-oligosacchride</intervention_name>
    <description>During this period subjects will receive 5.65 grams of Vivinal GOS supplements three times daily for four weeks</description>
    <arm_group_label>Galacto-oligosaccharide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Maltodextrin</intervention_name>
    <description>During this period subjects will receive 7.24 grams of maltodextrin supplements three times daily for four weeks</description>
    <arm_group_label>Maltodextrin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Based on medical history no gastrointestinal complaints can be defined.&#xD;
&#xD;
          2. Age 25 - 50 years and classified as 'robust' by the Fried frailty criteria, or age 70&#xD;
             - 85 years and classified as 'prefrail' by the Fried frailty criteria.&#xD;
&#xD;
          3. Body Mass Index (BMI) ≥ 20 and &lt; 30 kg/m2.&#xD;
&#xD;
          4. Weight-stable for at least 90 days prior to participation (no change in bodyweight,&#xD;
             i.e. &lt; 3kg).&#xD;
&#xD;
          5. Hemoglobin value of 8.2-11.0 mmol/L for men, 7.3-9.7 mmol/L for women.&#xD;
&#xD;
          6. C-reactive protein (CRP) value of &lt;10 mg/L.&#xD;
&#xD;
          7. Creatinin value of 60-115 μmol/L for men, 50-100 μmol/L for women.&#xD;
&#xD;
          8. Alanine transaminase (ALAT) value of &lt;45 U/L for men, 34 U/L for women.&#xD;
&#xD;
          9. Gamma-glutamyl transpeptidase (GGT) value of &lt;55 U/L for men, &lt;38 U/L for women.&#xD;
&#xD;
         10. Will be informed in case of any unexpected finding.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of severe cardiovascular, respiratory, urogenital, gastrointestinal/ hepatic,&#xD;
             hematological/immunologic, HEENT (head, ears, eyes, nose, throat),&#xD;
             dermatological/connective tissue, musculoskeletal, metabolic/nutritional, endocrine,&#xD;
             neurological diseases, major surgery and/or laboratory assessments which might limit&#xD;
             participation in or completion of the study protocol.&#xD;
&#xD;
          2. Self-admitted human immunodeficiency virus-positive state.&#xD;
&#xD;
          3. Disease with a life expectancy shorter than 5 years.&#xD;
&#xD;
          4. Abdominal surgery interfering with gastrointestinal function, upon judgment of the&#xD;
             medical doctor, who will decide on in- or exclusion based on the surgery applied.&#xD;
&#xD;
          5. Use of antibiotics products within 90 days prior to the study.&#xD;
&#xD;
          6. Use of other medication will be reviewed by a medical doctor, who will decide on in-&#xD;
             or exclusion based on the drug(s) used.&#xD;
&#xD;
          7. Use of laxatives within 14 days prior to the study.&#xD;
&#xD;
          8. Institutionalized (e.g. hospital or nursing home).&#xD;
&#xD;
          9. Pregnancy or lactation.&#xD;
&#xD;
         10. Plan to lose weight or follow a specific diet within the study period.&#xD;
&#xD;
         11. Alcohol intake &gt;14 units/week.&#xD;
&#xD;
         12. Drug use.&#xD;
&#xD;
         13. Blood donation within 30 days prior to the study.&#xD;
&#xD;
         14. Administration of probiotic or prebiotic supplements, investigational drugs or&#xD;
             participation in any scientific intervention study, which may interfere with this&#xD;
             study (to be decided by the principle investigator), in the 14 days prior to the&#xD;
             study.&#xD;
&#xD;
         15. History of side effects towards intake of prebiotic supplements.&#xD;
&#xD;
         16. Self-admitted lactose intolerance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A.A.M. Masclee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>March 3, 2017</study_first_submitted>
  <study_first_submitted_qc>March 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2017</study_first_posted>
  <last_update_submitted>September 6, 2018</last_update_submitted>
  <last_update_submitted_qc>September 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

